玻璃体内注射阿柏西普治疗增殖性糖尿病视网膜病变。 - Suppr | 超能文献

Intravitreal aflibercept for proliferative diabetic retinopathy.

作者信息

Brown David M, Wykoff Charles C

机构信息

Retina Consultants of Houston, Blanton Eye Institute, Houston Methodist Hospital, Houston, TX 77030, USA.

Retina Consultants of Houston, Blanton Eye Institute, Houston Methodist Hospital, Houston, TX 77030, USA.

出版信息

Lancet. 2017 Nov 11;390(10108):2141. doi: 10.1016/S0140-6736(17)32445-5. Epub 2017 Nov 9.

DOI:10.1016/S0140-6736(17)32445-5

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Intravitreal aflibercept for proliferative diabetic retinopathy.玻璃体内注射阿柏西普治疗增殖性糖尿病视网膜病变。

Lancet. 2017 Nov 11;390(10108):2141. doi: 10.1016/S0140-6736(17)32445-5. Epub 2017 Nov 9.

2

Intravitreal aflibercept for proliferative diabetic retinopathy.玻璃体内注射阿柏西普治疗增殖性糖尿病视网膜病变。

Lancet. 2017 Nov 11;390(10108):2140-2141. doi: 10.1016/S0140-6736(17)32426-1. Epub 2017 Nov 9.

3

Intravitreal aflibercept for proliferative diabetic retinopathy - Authors' reply.玻璃体内注射阿柏西普治疗增殖性糖尿病视网膜病变——作者回复

Lancet. 2017 Nov 11;390(10108):2141-2142. doi: 10.1016/S0140-6736(17)32422-4. Epub 2017 Nov 9.

4

Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.两年内糖尿病视网膜病变的变化：比较阿柏西普、贝伐单抗和雷珠单抗的随机临床试验的二次分析

JAMA Ophthalmol. 2017 Jun 1;135(6):558-568. doi: 10.1001/jamaophthalmol.2017.0821.

5

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.阿柏西普治疗既往贝伐单抗治疗无效的糖尿病性黄斑水肿：疗效及成功预测因素

Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1353-1354. doi: 10.1007/s00417-018-3951-7. Epub 2018 Mar 9.

6

CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.玻璃体腔内注射贝伐单抗、阿柏西普或雷珠单抗治疗糖尿病性黄斑水肿后血浆血管内皮生长因子水平的变化。

Retina. 2018 Sep;38(9):1801-1808. doi: 10.1097/IAE.0000000000002004.

7

Reply to the letter to the editor: Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.致编辑的信的回复：阿柏西普治疗既往贝伐单抗治疗无效的糖尿病性黄斑水肿：治疗结果及成功预测因素

Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1355-1356. doi: 10.1007/s00417-018-3952-6. Epub 2018 Mar 10.

8

Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.既往抗血管内皮生长因子治疗持续性糖尿病黄斑水肿后改用阿柏西普治疗

Am J Ophthalmol. 2016 Aug;168:290-291. doi: 10.1016/j.ajo.2016.05.015. Epub 2016 Jun 4.

9

Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.将治疗方案从贝伐单抗转换为阿柏西普以治疗持续性糖尿病性黄斑水肿。

Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1133-1140. doi: 10.1007/s00417-017-3624-y. Epub 2017 Feb 25.

10

Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.玻璃体内注射三种不同抗血管内皮生长因子药物后黄斑水肿的变化。

Retina. 2015 Mar;35(3):577-81. doi: 10.1097/IAE.0000000000000334.

引用本文的文献

1

Intravitreal aflibercept partially reverses severe non-proliferative diabetic retinopathy in treatment-naïve patients.玻璃体内注射阿柏西普可部分逆转未经治疗的严重非增殖性糖尿病视网膜病变。

J Int Med Res. 2021 Jan;49(1):300060520985369. doi: 10.1177/0300060520985369.

2

Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept.新型抗血管内皮生长因子药物 VEGF-Grab 的临床前疗效和安全性及其与阿柏西普的比较

Invest Ophthalmol Vis Sci. 2020 Nov 2;61(13):22. doi: 10.1167/iovs.61.13.22.